Tampa, Florida / Access Wire / December 8, 2023 / MEDFINITI BV and its U.S. subsidiaries, MEDFINITI, Inc. and HemWell MD LLC, are pleased to announce the introduction of HemWell, an innovative electrosurgical medical device that will change the approach to hemorrhoid treatment. This state-of-the-art device is designed to provide a minimally invasive and painless solution and represents a major advancement in patient care and experience.
HemWell is uniquely designed to meet the needs of millions of people who suffer from hemorrhoids. It provides a seamless and comfortable treatment experience, minimizing the discomfort and recovery time associated with traditional methods.
“The development of HemWell has been a journey driven by our commitment to patient health and the pursuit of better healthcare solutions,” said Michael Goeree, Founder and Chairman of MEDFINITI. “Our device is more than just a technological advancement; it’s new hope for people suffering from this common but often overlooked condition.”
“The success stories we have witnessed at Hemwell are a testament to our dedication and commitment to patient comfort and well-being,” said Dr. Steven Goldman, Chief Medical Officer of MEDFINITI. , bringing a much-needed change to hemorrhoid treatment.” efficacy. ”
Patented, FDA cleared (US) and soon to receive CE-MDR clearance (Europe), HemWell is designed for ease of use and effectiveness, eliminating the need for invasive procedures. will be reduced. Its innovative technology focuses on the root of the problem, ensuring faster, more comfortable recovery and an overall better patient experience.
MEDFINITI invites medical professionals and patients to learn more about HemWell and its benefits. For investor information about MEDFINITI and/or HemWell, more information about HemWell, or to schedule a HemWell demonstration, please contact us below.
Jennifer Ellerman, HemWell MD LLC
Phone: +1-813-775-6171
Email: info@hemwellmd.com
website: www.hemwellmd.com, www.hemwellrelief.com, www.hemwell.info, www.medfiniti.com
sauce: Medfinity BV
View original press release at accesswire.com